$MLTX
MoonLake Immunotherapeutics

2024 Q3 Form 10-Q Financial Statement

#000182158624000029 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.377M
YoY Change 36.86%
% of Gross Profit
Research & Development $35.74M
YoY Change 371.13%
% of Gross Profit
Depreciation & Amortization $32.51K
YoY Change
% of Gross Profit
Operating Expenses $43.11M
YoY Change 232.23%
Operating Profit -$43.11M
YoY Change 232.23%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.090M
YoY Change 411.41%
Pretax Income -$36.02M
YoY Change 210.81%
Income Tax $92.11K
% Of Pretax Income
Net Earnings -$35.39M
YoY Change 275.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.56
Diluted Earnings Per Share -$0.56
COMMON SHARES
Basic Shares Outstanding 62.90M shares
Diluted Shares Outstanding 62.90M shares

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $493.9M
YoY Change -0.41%
Cash & Equivalents $375.7M
Short-Term Investments $118.3M
Other Short-Term Assets $747.2K
YoY Change 86.8%
Inventory
Prepaid Expenses $15.98M
Receivables
Other Receivables $2.407M
Total Short-Term Assets $512.3M
YoY Change 2.46%
LONG-TERM ASSETS
Property, Plant & Equipment $581.4K
YoY Change 1371.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.065M
YoY Change
Total Long-Term Assets $5.897M
YoY Change 2722.39%
TOTAL ASSETS
Total Short-Term Assets $512.3M
Total Long-Term Assets $5.897M
Total Assets $518.2M
YoY Change 3.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.26M
YoY Change 242.06%
Accrued Expenses $9.370M
YoY Change 35.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.08M
YoY Change 94.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.631M
YoY Change 776.89%
Total Long-Term Liabilities $2.631M
YoY Change 879.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.08M
Total Long-Term Liabilities $2.631M
Total Liabilities $22.71M
YoY Change 114.74%
SHAREHOLDERS EQUITY
Retained Earnings -$190.0M
YoY Change 73.95%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $488.2M
YoY Change
Total Liabilities & Shareholders Equity $518.2M
YoY Change 3.6%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$35.39M
YoY Change 275.45%
Depreciation, Depletion And Amortization $32.51K
YoY Change
Cash From Operating Activities -$25.27M
YoY Change 173.24%
INVESTING ACTIVITIES
Capital Expenditures $132.2K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $58.41M
YoY Change -133.5%
Cash From Investing Activities $58.28M
YoY Change -133.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 183.1K
YoY Change
NET CHANGE
Cash From Operating Activities -25.27M
Cash From Investing Activities 58.28M
Cash From Financing Activities 183.1K
Net Change In Cash 33.19M
YoY Change -118.08%
FREE CASH FLOW
Cash From Operating Activities -$25.27M
Capital Expenditures $132.2K
Free Cash Flow -$25.41M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50080 usd
us-gaap Profit Loss
ProfitLoss
-74848699 usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39630
dei Entity Registrant Name
EntityRegistrantName
MOONLAKE IMMUNOTHERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1711963
dei Entity Address Address Line1
EntityAddressAddressLine1
Dorfstrasse 29
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Local Phone Number
LocalPhoneNumber
415108022
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7925524 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1935709 usd
CY2024Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
694959 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2630668 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
675343443 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
7306315 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
495501640 usd
dei Entity Small Business
EntitySmallBusiness
false
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1056862 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
514167302 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3628480 usd
CY2024Q3 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
10710603 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1444893 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35735514 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7585136 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72411709 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
43112009 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
12976743 usd
us-gaap Operating Expenses
OperatingExpenses
93510710 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43112009 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12976743 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-93510710 usd
CY2024Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-115629 usd
CY2023Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
39157 usd
us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-110878 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-441139 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3476448 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
397982 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36555563 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8142905 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-74450717 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-733037 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1552646 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
552386388 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
518213328 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7376495 usd
CY2023Q3 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-11590430 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-11619353 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-35390337 usd
dei Entity Address Country
EntityAddressCountry
CH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 us-gaap Liabilities
Liabilities
22711688 usd
CY2024Q3 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-36022318 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-36114424 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9426049 usd
us-gaap Net Income Loss
NetIncomeLoss
-73331005 usd
us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-19323 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33164512 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26095926 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-7068586 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-325510 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6930120 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2499990 usd
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
583426 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
17815336 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
513491019 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
526540115 usd
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15984425 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2102203 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
581378 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
320865 usd
CY2023Q4 us-gaap Assets
Assets
526540115 usd
CY2023Q4 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
1837684 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1197876 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3083416 usd
CY2023Q4 us-gaap Liabilities
Liabilities
13049096 usd
dei Trading Symbol
TradingSymbol
MLTX
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei City Area Code
CityAreaCode
41
dei Security12b Title
Security12bTitle
Class A ordinary share, par value $0.0001 per share
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
451169337 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3251197 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375656291 usd
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
118268400 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59838900 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2407062 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
5897150 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189988477 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2064575 usd
CY2024Q3 us-gaap Assets
Assets
518213328 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20081020 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12372813 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
8423468 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9965680 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
609969236 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2833970 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2357621 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116657472 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1509282 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23704087 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5391607 usd
us-gaap Operating Expenses
OperatingExpenses
39094204 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-39094204 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7089691 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1386313 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
18903070 usd
us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-36141647 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
241059 usd
us-gaap Net Income Loss
NetIncomeLoss
-28570184 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7621543 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6590259 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68766698 usd
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
2577187 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28923 usd
us-gaap Profit Loss
ProfitLoss
-36191727 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2193304 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3027215 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35822526 usd
CY2023Q1 mnlk Adjustments To Additional Paid In Capital Stamp Duty Fees
AdjustmentsToAdditionalPaidInCapitalStampDutyFees
4923 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-12218987 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21099001 usd
us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-74607640 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92106 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-724087 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1517694 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
508860 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3046538 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72941435 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17672 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
59112149 usd
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1497661 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
451285093 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-12353387 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001821586
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
dei Document Type
DocumentType
10-Q
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-431561 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
512316178 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
488195325 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
495675683 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15390117 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
499109955 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2952557 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3437291 usd
CY2023Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1425651 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-11619353 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3476448 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2023Q3 mnlk Noncontrolling Interest Increase From Capital Injection In Subsidiary
NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary
-2750515 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
489642186 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
513491019 usd
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1677208 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-13975521 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
263503 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
50 usd
CY2024Q1 mnlk Noncontrolling Interest Increase From Capital Injection In Subsidiary
NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary
-1609961 usd
CY2024Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
0 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
52540190 usd
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1828245 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-24758754 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
575618 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
530031497 usd
CY2024Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1842609 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-36114424 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-441139 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91298 usd
CY2024Q3 mnlk Adjustments To Additional Paid In Capital Stamp Duty Fees
AdjustmentsToAdditionalPaidInCapitalStampDutyFees
91799 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
495501640 usd
us-gaap Profit Loss
ProfitLoss
-74848699 usd
us-gaap Profit Loss
ProfitLoss
-36191727 usd
us-gaap Depreciation
Depreciation
83440 usd
us-gaap Depreciation
Depreciation
9869 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5348062 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5500499 usd
us-gaap Pension Expense Reversal Of Expense Noncash
PensionExpenseReversalOfExpenseNoncash
-2678 usd
us-gaap Pension Expense Reversal Of Expense Noncash
PensionExpenseReversalOfExpenseNoncash
-50740 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1189056 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-96364 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1350200 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
503626 usd
mnlk Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
5443 usd
mnlk Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7523329 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-869187 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8872919 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3149756 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-872121 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-117832 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
995404 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3195591 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68113589 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30433841 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
203334691 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
175732711 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
145414050 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
33681688 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
343953 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58264594 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-142051023 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52540190 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
451285093 usd
mnlk Payments Of Stamp Duty
PaymentsOfStampDuty
1470436 usd
mnlk Payments Of Stamp Duty
PaymentsOfStampDuty
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
91298 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51161002 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
451285093 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-295865 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-140047 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75513046 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
278660182 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
451169337 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39505627 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
375656291 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
318165809 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
554857 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">determining whether the in-process research and development expenditure (“IPR&amp;D”) has an alternative future use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">determining assumptions used in estimating the fair value of share-based compensation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the €100,000 Fundo de Garantia de Depósitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.</span></div>
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-26746 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-125581 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-557144 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-276491 usd
mnlk Number Of Operating Leases
NumberOfOperatingLeases
5 lease
CY2024Q3 mnlk Number Of Lease Contracts
NumberOfLeaseContracts
2 lease_contract
CY2024Q3 mnlk Number Of Lease Contracts
NumberOfLeaseContracts
2 lease_contract
us-gaap Profit Loss
ProfitLoss
-74800000 usd
CY2024Q3 mnlk Current Assets In Excess Of Current Liabilities
CurrentAssetsInExcessOfCurrentLiabilities
492200000 usd
CY2024Q3 us-gaap Cash
Cash
375700000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174833486 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3229714 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
178063200 usd
CY2024Q3 mnlk Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
7381811 usd
CY2023Q4 mnlk Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
842729 usd
CY2024Q3 mnlk Supply And Manufacturing Expense Current
SupplyAndManufacturingExpenseCurrent
6358892 usd
CY2023Q4 mnlk Supply And Manufacturing Expense Current
SupplyAndManufacturingExpenseCurrent
1205 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1496521 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1077478 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
747201 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
180791 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15984425 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2102203 usd
CY2024Q3 mnlk Supply And Manufacturing Expense Noncurrent
SupplyAndManufacturingExpenseNoncurrent
2064575 usd
CY2023Q4 mnlk Supply And Manufacturing Expense Noncurrent
SupplyAndManufacturingExpenseNoncurrent
8423468 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2064575 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
8423468 usd
CY2024Q3 mnlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7113098 usd
CY2023Q4 mnlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
911454 usd
CY2024Q3 mnlk Supply And Manufacturing Fees Payable Current
SupplyAndManufacturingFeesPayableCurrent
3044237 usd
CY2023Q4 mnlk Supply And Manufacturing Fees Payable Current
SupplyAndManufacturingFeesPayableCurrent
553459 usd
CY2024Q3 mnlk Accrued Consulting And Advisory Fees Current
AccruedConsultingAndAdvisoryFeesCurrent
307581 usd
CY2023Q4 mnlk Accrued Consulting And Advisory Fees Current
AccruedConsultingAndAdvisoryFeesCurrent
80695 usd
CY2024Q3 mnlk Accrued Legal Fees Current
AccruedLegalFeesCurrent
104317 usd
CY2023Q4 mnlk Accrued Legal Fees Current
AccruedLegalFeesCurrent
47095 usd
CY2024Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
141370 usd
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
244981 usd
CY2024Q3 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
10710603 usd
CY2023Q4 mnlk Trade And Other Payables Current
TradeAndOtherPayablesCurrent
1837684 usd
CY2024Q3 mnlk Accrued Research And Development Services And License Fees Current
AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent
3253581 usd
CY2023Q4 mnlk Accrued Research And Development Services And License Fees Current
AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent
1226281 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2922982 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2780219 usd
CY2024Q3 mnlk Accrued Supply And Manufacturing Fees Current
AccruedSupplyAndManufacturingFeesCurrent
894894 usd
CY2023Q4 mnlk Accrued Supply And Manufacturing Fees Current
AccruedSupplyAndManufacturingFeesCurrent
1603739 usd
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
484482 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
367976 usd
CY2024Q3 mnlk Accrued Consulting And Other Fees Current
AccruedConsultingAndOtherFeesCurrent
351774 usd
CY2023Q4 mnlk Accrued Consulting And Other Fees Current
AccruedConsultingAndOtherFeesCurrent
853905 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
17811 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
98000 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7925524 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6930120 usd
CY2023Q4 mnlk Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 period
CY2024Q3 mnlk Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 period
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P32M
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P39M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.047
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.049
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
386519 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1571589 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1242550 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
140313 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
140313 usd
CY2024Q3 mnlk Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
95627 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3576911 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
196309 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3380602 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1444893 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1935709 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1101661 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
78270 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
358583 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
39562 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1061029 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
117832 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
5398 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
5398 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
363981 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
39562 usd
us-gaap Lease Cost
LeaseCost
1066427 usd
us-gaap Lease Cost
LeaseCost
117832 usd
CY2024Q3 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
71107 usd
CY2023Q3 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
31175 usd
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
210387 usd
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
91596 usd
CY2024Q3 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
8387 usd
CY2023Q3 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
7784 usd
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
24814 usd
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
22872 usd
CY2024Q3 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
15338 usd
CY2023Q3 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
9280 usd
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
45380 usd
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
27265 usd
CY2024Q3 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-2609 usd
CY2023Q3 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
0 usd
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-7717 usd
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
0 usd
CY2024Q3 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
-2582 usd
CY2023Q3 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
0 usd
us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
-7639 usd
us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
0 usd
CY2024Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
64183 usd
CY2023Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
29679 usd
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
189899 usd
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
87203 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
192563 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
169455 chf
CY2023Q4 mnlk Shares Authorized
SharesAuthorized
600000000 shares
CY2023Q4 us-gaap Shares Issued
SharesIssued
62971929 shares
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
914828 shares
CY2024Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
16853 shares
CY2024Q1 mnlk Shares Authorized
SharesAuthorized
600000000 shares
CY2024Q1 us-gaap Shares Issued
SharesIssued
63869904 shares
CY2024Q2 mnlk Shares Authorized
SharesAuthorized
600000000 shares
CY2024Q2 us-gaap Shares Issued
SharesIssued
63869904 shares
CY2024Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17390 shares
CY2024Q3 mnlk Shares Authorized
SharesAuthorized
600000000 shares
CY2024Q3 us-gaap Shares Issued
SharesIssued
63887294 shares
CY2024Q3 mnlk Common Stock Conversion Ratio
CommonStockConversionRatio
33.638698
CY2023Q3 mnlk Sale Of Stock Stamp Duty Tax
SaleOfStockStampDutyTax
2800000 usd
CY2024Q1 mnlk Sale Of Stock Stamp Duty Tax
SaleOfStockStampDutyTax
1600000 usd
CY2024Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
91298 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-35390337 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9426049 usd
us-gaap Net Income Loss
NetIncomeLoss
-73331005 usd
us-gaap Net Income Loss
NetIncomeLoss
-28570184 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62896782 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62896782 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53517655 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53517655 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62803220 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62803220 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45485650 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45485650 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2024Q3 mnlk Number Of Share Based Compensation Plans
NumberOfShareBasedCompensationPlans
2 plan
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1800000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5300000 usd
CY2024Q3 mnlk Number Of Share Based Compensation Plans
NumberOfShareBasedCompensationPlans
2 plan
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1842609 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1425651 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5348062 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5500499 usd
CY2024Q3 mnlk Number Of Co Founders
NumberOfCoFounders
3 co-founder
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.003
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.002
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.001
CY2024Q3 mnlk Unrecognized Commitments And Contingencies
UnrecognizedCommitmentsAndContingencies
145100000 usd
CY2024Q3 us-gaap Noncurrent Assets
NoncurrentAssets
3832575 usd
CY2023Q4 us-gaap Noncurrent Assets
NoncurrentAssets
3949345 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001821586-24-000029-index-headers.html Edgar Link pending
0001821586-24-000029-index.html Edgar Link pending
0001821586-24-000029.txt Edgar Link pending
0001821586-24-000029-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mltx_2024q3xex311dasilva.htm Edgar Link pending
mltx_2024q3xex312bodenstedt.htm Edgar Link pending
mltx_2024q3xex321dasilva.htm Edgar Link pending
mltx_2024q3xex322bodenstedt.htm Edgar Link pending
mnlk-20240930.htm Edgar Link pending
mnlk-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnlk-20240930_cal.xml Edgar Link unprocessable
mnlk-20240930_def.xml Edgar Link unprocessable
mnlk-20240930_pre.xml Edgar Link unprocessable
mnlk-20240930_lab.xml Edgar Link unprocessable
mnlk-20240930_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending